Hipaakit
An artifact-generating HIPAA Security Rule 2026 compliance kit for solo and small-group US medical practices that auto-produces every mandated document, including the new AI-tool asset inventory.
A solo or two-doctor practice just inherited a stack of health-system-grade compliance obligations it has no staff to meet. The 2026 Security Rule overhaul makes every addressable safeguard mandatory and adds an AI-tool asset inventory, with a 180-day clock. The owner's two options today are a consultant retainer they can't justify or doing nothing and hoping — and 'nothing' is now a documented violation.
The solo or small-group US medical practice owner — the person personally on the hook for the practice's HIPAA posture, who today either pays a compliance consultant or carries the risk uncovered. The budget line already exists; it is currently spent on consultants or held as exposure.
A HIPAA Security Rule 2026 overhaul with a 180-day compliance clock from its publication — about as fresh as a regulatory window gets.
A solo or small-group US practice owner with the price stated and the alternative named (a consultant, or nothing) — specific enough to write a sales email against, with the price already anchored.
Cross-reference count of 3 is the weakest in the promoted set; five confirmed signals and kin ideas in adjacent runs only partially compensate.
The best-evidenced cheap-compliance play in its batch: a dated federal rule with a hard 180-day clock, a buyer named down to the price point, a verbatim price-elasticity quote showing latent demand, and pure-software economics that make self-serve at $49-99/mo viable by necessity.
The weakest cross-reference count of any near-threshold candidate in the batch, a blindspot argument that is the classic generic down-market case rather than a structural lock-out, and a window whose entire clock is pinned to the final-rule publication date — a timing slip moves everything.
Genesis doesn't invent in isolation — Hipaakit shares architecture with, or powers, these ideas.
Discussion
No comments yet — be the first to weigh in.